Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma

International Journal of Hematology

Volumn 82, Issue 5, 2005, Pages 397-405

  Ohno, Hitoshi ^a,e   Nishikori, Momoko ^b   Maesako, Yoshitomo ^c   Haga, Hironori ^d  

^a TAKEDA GENERAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TENRI HOSPITAL   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e Takeda General Hospital   (Japan)

Author keywords

Anaplastic large cell lymphoma; Ankyrin repeat; BCL3 gene; Chronic lymphocytic leukemia; NF B I B; t(14; 19)(q32; q13) translocation

Indexed keywords

ANKYRIN; CD30 ANTIGEN; CHIMERIC PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; MESSENGER RNA; MOLECULAR MARKER; PROTEIN BCL 3; PROTEIN P50; ONCOPROTEIN; PROTO ONCOGENE PROTEIN BCL 3; PROTO-ONCOGENE PROTEIN BCL-3; TRANSCRIPTION FACTOR; TUMOR MARKER;

ANAPLASTIC CARCINOMA; B CELL LYMPHOMA; CANCER PATIENT; CHROMOSOME 19Q; CHROMOSOME BAND; CHROMOSOME TRANSLOCATION; CHRONIC LYMPHATIC LEUKEMIA; GENE EXPRESSION; GENE LOCUS; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHATIC LEUKEMIA; LYMPHOMA CELL; MOLECULAR CLONING; NONHODGKIN LYMPHOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; B CELL LEUKEMIA; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETICS; HISTIOCYTIC LYMPHOMA; HUMAN CHROMOSOME; METABOLISM; PATHOLOGY;

CHROMOSOMES, HUMAN; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOMA, LARGE-CELL; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 33646440633     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05045     Document Type: Review

References (59)

1. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96:808-822.
2. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990;60:991-997.
3. Au WY, Horsman DE, Ohno H, Klasa RJ, Gascoyne RD. Bcl-3/IgH translocation (14;19)(q32;q13) in non-Hodgkin's lymphomas. Leuk Lymphoma. 2002;43:813-816.
4. McKeithan TW, Takimoto GS, Ohno H, et al. BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study. Genes Chromosomes Cancer. 1997;20:64-72.
5. Ueshima Y, Bird ML, Vardiman JW, Rowley JD. A 14;19 translocation in B-cell chronic lymphocytic leukemia: a new recurring chromosome aberration. Int J Cancer. 1985;36:287-290.
6. Yabumoto K, Ohno H, Doi S, et al. Involvement of the BCL3 gene in two patients with chronic lymphocytic leukemia. Int J Hematol. 1994;59:211-218.
7. Ohno H, Doi S, Yabumoto K, Fukuhara S, McKeithan TW. Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia. 1993;7:2057-2063.
8. + anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96:3681-3695.
9. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623-5637.
10. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:1495-1505.
11. Nishikori M, Maesako Y, Ueda C, Kurata M, Uchiyama T, Ohno H. High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood. 2003;101:2789-2796.
12. McKeithan TW, Rowley JD, Shows TB, Diaz MO. Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1987;84:9257-9260.
13. McKeithan TW, Ohno H, Diaz MO. Identification of a transcriptional unit adjacent to the breakpoint in the 14;19 translocation of chronic lymphocytic leukemia. Genes Chromosomes Cancer. 1990;1:247-255.
14. McKeithan TW, Ohno H, Dickstein J, Hume E. Genomic structure of the candidate proto-oncogene BCL3. Genomics. 1994;24:120-126.
15. Robinson HM, Taylor KE, Jalali GR, Cheung KL, Harrison CJ, Moorman AV. t(14;19)(q32;q13): a recurrent translocation in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2004;39:88-92.
16. Ong ST, Hackbarth ML, Degenstein LC, Baunoch DA, Anastasi J, McKeithan TW. Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene. 1998;16:2333-2343.
17. Franzoso G, Carlson L, Scharton-Kersten T, et al. Critical roles for the Bcl-3 oncoprotein in T cell-mediated immunity, splenic microarchitecture, and germinal center reactions. Immunity. 1997;6:479-490.
18. Mitchell TC, Hildeman D, Kedl RM, et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol. 2001;2:397-402.
19. Lux SE, John KM, Bennett V. Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins. Nature. 1990;344:36-42.
20. Bork P. Hundreds of ankyrin-like repeats in functionally diverse proteins: mobile modules that cross phyla horizontally? Proteins. 1993;17:363-374.
21. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301-310.
22. Inoue J, Kerr LD, Kakizuka A, Verma IM. IκBγ, a 70 kd protein identical to the C-terminal half of p110 NF-κB: a new member of the IκB family. Cell. 1992;68:1109-1120.
23. Whiteside ST, Epinat JC, Rice NR, Israel A. IκBε, a novel member of the IκB family, controls RelA and cRel NF-κB activity. EMBO J. 1997;16:1413-1426.
24. Yamazaki S, Muta T, Takeshige K. A novel IκB protein, IκB-ζ, induced by proinflammatory stimuli, negatively regulates nuclear factor-κB in the nuclei. J Biol Chem. 2001;276:27657-27662.
25. Zhang Q, Didonato JA, Karin M, McKeithan TW. BCL3 encodes a nuclear protein which can alter the subcellular location of NF-κB proteins. Mol Cell Biol. 1994;14:3915-3926.
26. Michel F, Soler-Lopez M, Petosa C, Cramer P, Siebenlist U, Muller CW. Crystal structure of the ankyrin repeat domain of Bcl-3: a unique member of the IκB protein family. EMBO J. 2001;20:6180-6190.
27. Nolan GP, Fujita T, Bhatia K, et al. The bcl-3 proto-oncogene encodes a nuclear IκB-like molecule that preferentially interacts with NF-κB p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol. 1993;13:3557-3566.
28. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-κB-mediated inhibition. Nature. 1992;359:339-342.
29. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev. 1993;7:1354-1363.
30. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell. 1993;72:729-739.
31. Drexler HG, Matsuo AY, MacLeod RA. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk Res. 2000;24:881-911.
32. Maesako Y, Akasaka T, Uchiyama T, Ohno H. Improved DNA-based polymerase chain reaction amplification of t(2;5)(p23;q35) breakpoints. Int J Hematol. 2000;72:110-111.
33. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191:395-402.
34. Wellmann A, Thieblemont C, Pittaluga S, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000;96:398-404.
35. Rassidakis GZ, Oyarzo MP, Medeiros LJ. BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Blood. 2003;102:1146-1147.
36. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347.
37. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191:207-212.
38. Nishikori M, Ohno H, Haga H, Uchiyama T. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-κB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci. 2005;96:487-497.
39. Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med. 2002;196:605-617.
40. Siegler G, Kremmer E, Gonnella R, Niedobitek G. Epstein-Barr virus encoded latent membrane protein 1 (LMP1) and TNF receptor associated factors (TRAF): colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma. Mol Pathol. 2003;56:156-161.
41. Rassidakis GZ, Sarris AH, Herling M, et al. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage. Am J Pathol. 2001;159:527-535.
42. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood. 2003;101:681-689.
43. Schlette EJ, Medeiros LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22:1682-1688.
44. Durkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell. 1992;68:421-427.
45. Horie R, Higashihara M, Watanabe T. Hodgkin's lymphoma and CD30 signal transduction. Int J Hematol. 2003;77:37-47.
46. Lee SY, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med. 1996;183:669-674.
47. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell. 1996;84:551-562.
48. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood. 2000;96:4307-4312.
49. Bundy DL, McKeithan TW. Diverse effects of BCL3 phosphorylation on its modulation of NF-κB p52 homodimer binding to DNA. J Biol Chem. 1997;272:33132-33139.
50. Turco MC, Romano MF, Petrella A, Bisogni R, Tassone P, Venuta S. NF-κB/Rel-mediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia. 2004;18:11-17.
51. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin- anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity. Mol Cell Biol. 1998;18:6951-6961.
52. Kuefer MU, Look AT, Pulford K, et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood. 1997;90:2901-2910.
53. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood. 2000;96:4319-4327.
54. Horie R, Watanabe M, Ishida T, et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-κB activation in anaplastic large cell lymphoma. Cancer Cell. 2004;5:353-364.
55. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene. 2000;19:1123-1131.
56. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-κB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 2003;63:8293-8301.
57. Robanus-Maandag EC, Bosch CA, Kristel PM, et al. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol. 2003;201:75-82.
58. Akervall JA, Michalides RJ, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997;79:380-389.
59. Viatour P, Dejardin E, Warnier M, et al. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity. Mol Cell. 2004;16:35-45.